Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA).  The meeting will be open to the public.

*Name of Committee*: Endocrinologic and Metabolic Drugs Advisory Committee.                

*General Function of the Committee*:  To provide advice and recommendations to the agency on FDA's regulatory issues.                

*Date and Time*:  The meeting will be held on July 26 and 27, 2001, 8 a.m. to 5 p.m.                

*Location*: Holiday Inn, Versailles Ballrooms, 8120 Wisconsin Ave., Bethesda, MD.                

*Contact*: Kathleen Reedy  or LaNise Giles, Center for Drug Evaluation and Research (HFD-21), Food and Drug                           ( print page 30936)                        Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857,  301-827-7001, FAX 301-827-6776, or e-mail: reedyk@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12536.  Please call the Information Line for up-to-date information on this meeting.                

*Agenda*:  On July 26, 2001, the committee will discuss new drug application (NDA)  21-332, Symlin                    TM                     (pramlintide acetate, Amylin Pharmaceuticals, Inc.) as an adjunctive  therapy to insulin to improve glycemic and metabolic control in patients with type 1 or type 2 diabetes mellitus alone or in combination with oral hypoglycemic agents.  On July 27, 2001, the committee will discuss NDA 21-318, Fortéo                    TM                     (teriparatide injection, rDNA origin, Eli Lilly and Co.) for the treatment of osteoporosis in men and in postmenopausal women.                

*Procedure*:  Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.  Written submissions may be made to the contact person by July 20, 2001.  Oral presentations from the public will be scheduled between approximately 11 a.m. and 11:30 a.m. each day.  Time allotted for each presentation may be limited.  Those desiring to make formal oral presentations should notify the contact person before July 20, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.                

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 31, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01-14410 Filed 6-7-01; 8:45 am]

BILLING CODE 4160-01-S